Aroa Biosurgery reported positive results from a US clinical trial showing its Symphony wound care product improved healing outcomes for diabetic foot ulcers. In a study of 143 patients across 10 US sites, 55% of ulcers treated with Symphony plus standard care achieved complete closure within 12 weeks, compared to 35% with standard care alone. Symphony also reduced the average healing time by 7.8 days. These results provide strong clinical evidence supporting Symphony's effectiveness and may boost its adoption and reimbursement in the US market.
Aroa Biosurgery's Symphony wound care product is the subject, with Pluang market data providing context for health-sector stocks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 05, 2026 07:51 WIB: out of 100 priced US health stocks, 25 rose and 74 fell. Notable moves include McKesson Corporation (MCK) rising 5.68% to USD 902.28 with a typical hold time of 74 days, while Incyte Corporation (INCY) and AbCellera Biologics Inc (ABCL) fell by 6.61% and 5.48% to USD 113.33 and USD 13.79 respectively, with typical hold times of 32 and 41 days.
U.S. President Donald Trump warned South Korea to sign on soon to the $50 billion Alaska LNG project or face higher charges, possibly tariffs, though he did not specify details. South Korea is still evaluating the project based on commercial viabilit...
Zcash has registered a lobbyist in Washington, DC, aiming to influence US cryptocurrency policies, including tax rules and market structure. This move is part of Zcash's effort to promote privacy-focused crypto regulations. Market watchers see this a...
CSL Limited has signed an exclusive licensing deal with Swiss biotech Alentis Therapeutics to develop and commercialize lixudebart, a drug in Phase 2 trials for rare autoimmune kidney disease ANCA-associated vasculitis. The drug targets inflammation ...
GraniteShares 2x Long MU Daily ETF (MULL), which offers double the daily performance of Micron stock, is rated Hold due to expected short-term volatility. Micron's growth prospects remain strong, supported by expanding production capacity, high deman...
A wallet holding a large short position of about 78,000 Ether (ETH) on Hyperliquid experienced an unrealized loss of approximately $30.29 million as of October 5. The position was valued at around $213 million with an average opening price of $2,340 ...
